Show simple item record

dc.contributor.authorSchmid, C
dc.contributor.authorKuemmerle, A
dc.contributor.authorBlum, J
dc.contributor.authorGhabri, S
dc.contributor.authorKande, V
dc.contributor.authorMutombo, W
dc.contributor.authorIlunga, M
dc.contributor.authorLumpungu, I
dc.contributor.authorMutanda, S
dc.contributor.authorNganzobo, P
dc.contributor.authorTete, D
dc.contributor.authorMubwa, N
dc.contributor.authorKisala, M
dc.contributor.authorBlesson, S
dc.contributor.authorMordt, O V
dc.date.accessioned2013-03-13T12:20:12Z
dc.date.available2013-03-13T12:20:12Z
dc.date.issued2012-11-29
dc.identifier.citationIn-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. 2012, 6 (11):e1920 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735
dc.identifier.pmid23209861
dc.identifier.doi10.1371/journal.pntd.0001920
dc.identifier.urihttp://hdl.handle.net/10144/272002
dc.description.abstractTrypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use.
dc.language.isoenen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseases and Open Accessen_GB
dc.titleIn-hospital safety in field conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. B. Gambiense Sleeping Sicknessen
dc.contributor.departmentDepartment of Medicines Research, Swiss Tropical and Public Health Institute, Basel, Switzerland.en_GB
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB
refterms.dateFOA2019-03-04T10:17:16Z
html.description.abstractTrypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use.


Files in this item

Thumbnail
Name:
pntd.0001920.pdf
Size:
286.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record